Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study.
ACA, Acrodermatitis chronica atrophicans
CFQ, Cognitive Failure Questionnaire
CIS, Checklist Individual Strength
EM, Erythema migrans
LB, Lyme borreliosis
PCR, Polymerase Chain Reaction
PHQ-15, Patient Health Questionnaire
PTLDS, Post-treatment Lyme Disease Syndrome
SF-36, SF-36 item Health Survey
TiC-P, Treatment Inventory of Costs in Patients with psychiatric disorders
s.l., sensu lato
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Concerns about long-lasting symptoms attributed to Lyme borreliosis (LB) are widespread in the Western world, while such symptoms are highly prevalent in the general population. In the largest prospective study to date, adults with physician-confirmed LB were included at the start of antibiotic treatment. Primary outcomes, prevalence of persistent symptoms and symptom severity, were assessed using three-monthly standardised questionnaires during one year. Persistent symptoms were defined as impaired scores for fatigue (CIS, subscale fatigue), cognitive impairment (CFQ) or pain (SF-36, subscale bodily pain) ≥6 months, with onset <6 months. Outcomes were compared with a longitudinal general population and a tick-bite cohort without LB as a reference. Of 1135 LB patients (94•8% erythema migrans, 5•2% disseminated LB), 1084 fulfilled primary analysis criteria, as well as 1942 population and 1887 tick-bite controls. Overall prevalence of persistent symptoms in LB patients was 27•2% (95%CI, 24•7%-29•7%); 6•0% and 3•9% higher than in population (21•2%, 95%CI, 19•3%-23•1%; In treated LB patients, persistent symptoms were significantly more prevalent and symptoms were more severe than in individuals without LB, although the background prevalence was substantial. This suggests an association, either direct or indirect, between persistent symptoms and LB in a relatively small subset of patients. ZonMw; Dutch Ministry of Health, Welfare and Sport.
Sections du résumé
BACKGROUND
BACKGROUND
Concerns about long-lasting symptoms attributed to Lyme borreliosis (LB) are widespread in the Western world, while such symptoms are highly prevalent in the general population.
METHODS
METHODS
In the largest prospective study to date, adults with physician-confirmed LB were included at the start of antibiotic treatment. Primary outcomes, prevalence of persistent symptoms and symptom severity, were assessed using three-monthly standardised questionnaires during one year. Persistent symptoms were defined as impaired scores for fatigue (CIS, subscale fatigue), cognitive impairment (CFQ) or pain (SF-36, subscale bodily pain) ≥6 months, with onset <6 months. Outcomes were compared with a longitudinal general population and a tick-bite cohort without LB as a reference.
FINDINGS
RESULTS
Of 1135 LB patients (94•8% erythema migrans, 5•2% disseminated LB), 1084 fulfilled primary analysis criteria, as well as 1942 population and 1887 tick-bite controls. Overall prevalence of persistent symptoms in LB patients was 27•2% (95%CI, 24•7%-29•7%); 6•0% and 3•9% higher than in population (21•2%, 95%CI, 19•3%-23•1%;
INTERPRETATION
CONCLUSIONS
In treated LB patients, persistent symptoms were significantly more prevalent and symptoms were more severe than in individuals without LB, although the background prevalence was substantial. This suggests an association, either direct or indirect, between persistent symptoms and LB in a relatively small subset of patients.
FUNDING
BACKGROUND
ZonMw; Dutch Ministry of Health, Welfare and Sport.
Identifiants
pubmed: 34557833
doi: 10.1016/j.lanepe.2021.100142
pii: S2666-7762(21)00119-8
pmc: PMC8454881
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100142Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
All authors have completed the ICMJE uniform disclosure form and declare: JWH, LABJ, and CCvdW report grants from the Netherlands Organization for Health Research and Development (ZonMw), and the Dutch Ministry of Health, Welfare and Sport (VWS); LABJ has a patent on Lyme diagnosis issued; JWH was supported by the European Union's regional development fund (INTERREG) as part of the NorthTick project; all other authors have no conflicts to declare.
Références
Clin Infect Dis. 2015 Dec 15;61(12):1800-6
pubmed: 26385994
PLoS One. 2011 Mar 31;6(3):e18220
pubmed: 21483819
Clin Infect Dis. 2020 Jul 11;71(2):440-452
pubmed: 31773171
Clin Microbiol Infect. 2011 Jan;17(1):69-79
pubmed: 20132258
Am J Med. 2015 Feb;128(2):181-4
pubmed: 25447620
Am J Med. 2018 Jun;131(6):592-594
pubmed: 29284115
J Psychosom Res. 1994 Jul;38(5):383-92
pubmed: 7965927
J Psychosom Res. 2017 Jul;98:40-46
pubmed: 28554371
Health Psychol. 2018 Jun;37(6):530-543
pubmed: 29781654
BMJ. 2006 Sep 16;333(7568):575
pubmed: 16950834
BMC Infect Dis. 2019 Apr 15;19(1):324
pubmed: 30987580
Am J Med. 2010 Jan;123(1):79-86
pubmed: 20102996
Eur J Neurol. 2010 Jan;17(1):118-23
pubmed: 19645771
PLoS One. 2016 May 25;11(5):e0155884
pubmed: 27223465
Int J Infect Dis. 2013 Jun;17(6):e443-9
pubmed: 23462300
J Clin Epidemiol. 1998 Nov;51(11):1055-68
pubmed: 9817123
Clin Infect Dis. 2020 Dec 15;71(12):3118-3124
pubmed: 31996890
Clin Infect Dis. 2006 Nov 1;43(9):1089-134
pubmed: 17029130
Parasit Vectors. 2015 Mar 15;8:161
pubmed: 25889086
BMC Infect Dis. 2019 Oct 7;19(1):833
pubmed: 31590634
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Acta Neurol Scand. 2011 Nov;124(5):349-54
pubmed: 21303350
J Infect Dis. 2001 Feb 1;183(3):453-60
pubmed: 11133377
Int J Behav Med. 1996;3(2):104-22
pubmed: 16250758
PLoS One. 2017 Jul 24;12(7):e0181807
pubmed: 28742149
J Neurol. 2015 Nov;262(11):2572-7
pubmed: 26410742
J Neurol. 2016 Jan;263(1):17-24
pubmed: 26459093
Clin Infect Dis. 2012 Aug;55(3):343-50
pubmed: 22523260
N Engl J Med. 2016 Mar 31;374(13):1209-20
pubmed: 27028911
BMJ. 2020 May 26;369:m1041
pubmed: 32457042